Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic disorders worldwide. Although its true prevalence is difficult to determine ...

Inside every cell, thousands of molecular signals collide, overlap, and compensate, obscuring the true drivers of gene expression. Scientists have now developed a way to silence that cellular noise, ...

To model bacterial life, Thornburg and his colleagues turned to one of its simplest examples: a bacterial cell with a ...

Drug-resistant epilepsy affects millions worldwide, with focal cortical dysplasia (FCD) as one of the leading causes. Yet its ...

The Lord called Eugene Thompson home on March 2, 2026; he was 89 years old. Born on August 17, 1936, on his grandparents’ farm in Randolph County, Indiana, to Nolan C. and S. Pearl (Eads) Thompson; he ...

A warehouse worker, Teddy (played by Jesse Plemons), accuses high-powered CEO Michelle (Emma Stone) of being an ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about building a steady cadence of biopsies and treatments, ...

A simulated cell in the early stages of division. Left half shows membrane (green cubes), and ribosomes (yellow/purple) interwoven through in the cell’s chromosome (red). Right side shows all the ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's ...

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team ...

Good morning, everyone, and welcome to the Abeona Therapeutics Full Year 2025 Results Conference Call. [Operator Instructions] Please note this conference is being recor ...